Naegis is driven to create new therapies for serious eye diseases that are leading causes blindness
Building on its expertise in anti-inflammatory drug discovery, the company has designed and produced a series of compounds that have the potential to be beneficial in the treatment of serious eye diseases, including those that affect the back of the eye, through delivery to the retina by an eye drop.
icon INFLAMMATORY EYE DISEASES
Inflammatory eye diseases may result in damage of eye tissue, leading to reduced vision and/or vision loss.
What we do
Chronic inflammatory disease represents an enormous societal and economic burden, particularly in an aging population, impacting both quality and quantity of life. Naegis Pharmaceuticals Inc. is driven to discover new therapies that target underlying chronic inflammatory processes in disease. The Naegis research team seeks to design new drugs that offer safer and more effective treatment options for patients, focusing first on serious eye conditions that result in damage to the back of the eye, with a program directed towards blocking the synthesis of pro-inflammatory mediators in disease. [...]
Meet Our Team
Founder and CEO
Vice President Pre-Clinical Research
Clinical Advisor
icon
Suite 720, 999 West Broadway Vancouver, B.C. V5Z 1K5
icon
This email address is being protected from spambots. You need JavaScript enabled to view it.
icon
604-235-1682